Objectives: Little is known about the longitudinal course of pediatric acute-onset neuropsychiatric syndrome (PANS) because existing literature is primarily cross-sectional. To begin to address this gap, two digital platforms were used to prospectively monitor neuropsychiatric symptoms in children with PANS. The aim was to identify baseline clinical characteristics that would predict the course of neuropsychiatric symptoms over 12 weeks. We compared relative compliance between two electronic data acquisition platforms and evaluated agreement between parent-child ratings of symptoms. Methods: For 12 weeks, 20 children with PANS and their parents completed weekly rating scales of neuropsychiatric symptoms on Research Electronic Data Capture (REDCap) and concurrently parents completed tri-weekly ratings on My Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) Chart, a symptom monitoring website. Longitudinal data were analyzed by using regression analyses. Results: Greater duration of time between onset of PANS and study enrollment was associated with worsening of parent-rated neuropsychiatric symptoms over 12 weeks (p = 0.05). Higher scores on parents' Caregiver Burden Inventory at baseline predicted that children would report more severe symptoms over the 12-week period (p = 0.01). Compliance rates for parents were 86.3% for the weekly REDCap PANS Symptoms Rating Scale compared with 53.8% for the tri-weekly My PANDAS Chart ratings. There was moderate agreement between children and parents on the PANS Symptom Rating Scale (r = 0.55, p < 0.0001). Conclusion: Our study highlights the utility of electronic methods for tracking longitudinal symptoms in children with PANS and suggests that particular baseline characteristics (e.g., delay in identification and treatment of PANS, greater caregiver burden) may be indicative of a differential trajectory of PANS course, with more severe symptoms over the short term. clinicaltrials.gov NCT04382716.
|Original language||English (US)|
|Number of pages||7|
|Journal||Journal of child and adolescent psychopharmacology|
|State||Published - Mar 2021|
Bibliographical noteFunding Information:
1Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis, Minnesota, USA. 2Clinical and Translational Science Institute, University of Minnesota, Minneapolis, Minnesota, USA. Parts of this study were presented as posters at the 66th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), Chicago, IL, October 2019 and at the Virtual Annual Meeting of the AACAP, October 2020. Funding: Funded by the University of Minnesota Grant-in-Aid of Research, Artistry, and Scholarship #210170.
© Copyright 2021, Mary Ann Liebert, Inc., publishers 2021.
- electronic data collection
- prospective study
- symptom monitoring
PubMed: MeSH publication types
- Journal Article